Journal
GUT AND LIVER
Volume 9, Issue 5, Pages 607-614Publisher
EDITORIAL OFFICE GUT & LIVER
DOI: 10.5009/gnl14135
Keywords
Bone metabolism; Hydrogen potassium ATPase; Osteoclasts; Osteoporosis; Proton pump inhibitors
Categories
Funding
- Eulji Research Grant [EJRG-09-018-12E11]
Ask authors/readers for more resources
Background/Aims: Proton pump inhibitors (PPIs) act by irreversibly binding to the H+-K+-ATPase of the proton pump in parietal cells and may possibly affect the vacuolar H+-ATPase in osteoclasts. Methods: We investigated the effect of 8 weeks of PPI treatment on the parameters of bone turnover and compared PPI with revaprazan, which acts by reversibly binding to H+-K+-ATPase in proton pumps. This study was a parallel randomized controlled trial. For 8 weeks, either a PPI or revaprazan was randomly assigned to patients with gastric ulcers. The parameters of bone turnover were measured at the beginning of and after the 8-week treatment period. Results: Twenty-six patients (PPI, n=13; revaprazan, n=13) completed the intention-to-treat analysis. After the 8-week treatment period, serum calcium and urine deoxypyridinoline (DPD) were increased in the PPI group (serum calcium, p=0.046; urine DPD, p=0.046) but not in the revaprazan group. According to multivariate linear regression analysis, age >= 60 years was an independent predictor for the changes in serum calcium and urine DPD. Conclusions: In elderly patients, administering a PPI for 8 weeks altered bone parameters. Our study suggested that PPIs might directly alter bone metabolism via the vacuolar H+-ATPase in osteoclasts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available